Applied Molecular Transport’s shot at beating Humira in UC fails in mid-stage study, sinking shares nearly 30%
Applied Molecular Transport’s lead program hit a roadblock Wednesday with a mid-stage flop in ulcerative colitis, failing to perform better than Humira.
When tested in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
